Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms
Abbott Laboratories received FDA approval for its Volt Pulsed Field Ablation system to treat atrial fibrillation, entering a competitive U.S. market. The company also announced a planned $23 billion acquisition of Exact Sciences and addressed an FDA alert on certain FreeStyle Libre sensors. Abbott shares last closed in the mid-$120s before the Christmas holiday.